Send to

Choose Destination
Nat Rev Immunol. 2009 Jan;9(1):28-38. doi: 10.1038/nri2451.

Harnessing invariant NKT cells in vaccination strategies.

Author information

Tumour Immunology Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DU, UK.


To optimize vaccination strategies, it is important to use protocols that can 'jump-start' immune responses by harnessing cells of the innate immune system to assist the expansion of antigen-specific B and T cells. In this Review, we discuss the evidence indicating that invariant natural killer T (iNKT) cells can positively modulate dendritic cells and B cells, and that their pharmacological activation in the presence of antigenic proteins can enhance antigen-specific B- and T-cell responses. In addition, we describe structural and kinetic analyses that assist in the design of optimal iNKT-cell agonists that could be used in the clinical setting as vaccine adjuvants.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center